Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 16 AL 30

A review: treatment of Alzheimer's disease discovered in repurposed agents

Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL.

Dement Geriatr Cogn Disord. 2013;35(1-2):1-22. doi: 10.1159/000345791. Epub 2013 Jan 9.

The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention

Heo JH, Hyon-Lee, Lee KM.

Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):120-5. doi: 10.1177/1533317512473193. Epub 2013 Jan 9.

A 10-year perspective on donepezil

Cheewakriengkrai L, Gauthier S.

Expert Opin Pharmacother. 2013 Feb;14(3):331-8. doi: 10.1517/14656566.2013.760543. Epub 2013 Jan 14.

Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor

Hsu CK, Hsu CC, Lee JY, Kuo YM, Pai MC.

J Am Acad Dermatol. 2013 Feb;68(2):e46-8. doi: 10.1016/j.jaad.2012.07.012.

The role of vitamin D in Alzheimer's disease: possible genetic and cell signaling mechanisms

Lu'o'ng KV, Nguyen LT.

Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):126-36. doi: 10.1177/1533317512473196. Epub 2013 Jan 15.

Drug development status for Alzheimer's disease: present scenario

Misra S, Medhi B.

Neurol Sci. 2013 Jun;34(6):831-9. doi: 10.1007/s10072-013-1316-x. Epub 2013 Feb 8.

[Blood-brain barrier and Alzheimer's disease]

Kuwahara H, Nishida Y, Yokota T.

Brain Nerve. 2013 Feb;65(2):145-51.

Targeting nascent soluble Aβ42 for potential Alzheimer drug development

Zhang M, Hausmann L, Song W.

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.

Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease

Noetzli M, Eap CB.

Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.

Alzheimer's disease and antioxidant therapy: how long how far?

Teixeira J, Silva T, Andrade PB, Borges F.

Curr Med Chem. 2013;20(24):2939-52. doi: 10.2174/1871523011320240001.

Multitarget drugs of plants origin acting on Alzheimer's disease

Russo P, Frustaci A, Del Bufalo A, Fini M, Cesario A.

Curr Med Chem. 2013;20(13):1686-93. doi: 10.2174/0929867311320130008.

Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease

Solé-Padullés C, Bartrés-Faz D, Lladó A, Bosch B, Peña-Gómez C, Castellví M, Rami L, Bargalló N, Sánchez-Valle R, Molinuevo JL.

J Clin Psychopharmacol. 2013 Apr;33(2):199-205. doi: 10.1097/JCP.0b013e3182825bfd.

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012)

Belluti F, Rampa A, Gobbi S, Bisi A.

Expert Opin Ther Pat. 2013 May;23(5):581-96. doi: 10.1517/13543776.2013.772983. Epub 2013 Feb 21.

Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study

Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR; DIADS-2 Research Group.

J Clin Pharmacol. 2013 Feb;53(2):234-9. doi: 10.1177/0091270012445793. Epub 2013 Jan 24.

Memantine-associated renal impairment in a patient with Alzheimer's disease

Horikawa N, Yamada H, Uchimura N.

Psychiatry Clin Neurosci. 2013 Feb;67(2):126. doi: 10.1111/pcn.12020.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias